Mizuho cut shares of Achaogen (NASDAQ:AKAO) from a buy rating to a neutral rating in a research note published on Friday, Marketbeat.com reports.

Several other research firms have also issued reports on AKAO. Stifel Nicolaus lifted their price objective on shares of Achaogen from $14.00 to $22.00 and gave the company a buy rating in a research note on Tuesday, August 7th. BidaskClub lowered shares of Achaogen from a sell rating to a strong sell rating in a research note on Wednesday, July 18th. Zacks Investment Research raised shares of Achaogen from a hold rating to a buy rating and set a $4.75 price objective for the company in a research note on Wednesday, October 10th. Needham & Company LLC lowered shares of Achaogen from a buy rating to a hold rating in a research note on Tuesday, August 7th. Finally, SunTrust Banks reduced their price objective on shares of Achaogen from $16.00 to $10.00 and set a buy rating for the company in a research note on Monday, August 20th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $14.81.

Shares of AKAO stock traded down $0.40 on Friday, hitting $2.25. The company’s stock had a trading volume of 1,656,391 shares, compared to its average volume of 579,029. The company has a current ratio of 3.79, a quick ratio of 3.79 and a debt-to-equity ratio of 0.42. Achaogen has a fifty-two week low of $2.10 and a fifty-two week high of $15.00. The firm has a market cap of $139.24 million, a PE ratio of -0.71 and a beta of 0.67.

Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Achaogen by 2.1% during the 1st quarter. BlackRock Inc. now owns 2,898,459 shares of the biopharmaceutical company’s stock worth $37,536,000 after acquiring an additional 60,613 shares during the last quarter. Granahan Investment Management Inc. MA acquired a new position in Achaogen during the 2nd quarter worth $1,220,000. Teton Advisors Inc. lifted its position in Achaogen by 324.2% during the 2nd quarter. Teton Advisors Inc. now owns 140,000 shares of the biopharmaceutical company’s stock worth $1,212,000 after acquiring an additional 107,000 shares during the last quarter. Gabelli Funds LLC lifted its position in Achaogen by 18.6% during the 2nd quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock worth $1,787,000 after acquiring an additional 32,400 shares during the last quarter. Finally, Gamco Investors INC. ET AL lifted its position in Achaogen by 43.1% during the 2nd quarter. Gamco Investors INC. ET AL now owns 94,700 shares of the biopharmaceutical company’s stock worth $820,000 after acquiring an additional 28,500 shares during the last quarter. 60.17% of the stock is owned by hedge funds and other institutional investors.

About Achaogen

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Recommended Story: Rule of 72

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.